GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prime Medicine Inc (NAS:PRME) » Definitions » Debt-to-EBITDA

Prime Medicine (Prime Medicine) Debt-to-EBITDA : -0.06 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Prime Medicine Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Prime Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $9.28 Mil. Prime Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.36 Mil. Prime Medicine's annualized EBITDA for the quarter that ended in Dec. 2023 was $-213.18 Mil. Prime Medicine's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Prime Medicine's Debt-to-EBITDA or its related term are showing as below:

PRME' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.25   Med: -0.12   Max: -0.07
Current: -0.07

During the past 4 years, the highest Debt-to-EBITDA Ratio of Prime Medicine was -0.07. The lowest was -0.25. And the median was -0.12.

PRME's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs PRME: -0.07

Prime Medicine Debt-to-EBITDA Historical Data

The historical data trend for Prime Medicine's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prime Medicine Debt-to-EBITDA Chart

Prime Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
- -0.12 -0.25 -0.07

Prime Medicine Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 -0.17 -0.14 -0.09 -0.06

Competitive Comparison of Prime Medicine's Debt-to-EBITDA

For the Biotechnology subindustry, Prime Medicine's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prime Medicine's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prime Medicine's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Prime Medicine's Debt-to-EBITDA falls into.



Prime Medicine Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Prime Medicine's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.276 + 4.357) / -186.639
=-0.07

Prime Medicine's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.276 + 4.357) / -213.184
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Prime Medicine  (NAS:PRME) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Prime Medicine Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Prime Medicine's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Prime Medicine (Prime Medicine) Business Description

Traded in Other Exchanges
N/A
Address
21 Erie Street, Cambridge, MA, USA, 02139
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Executives
Gv 2019 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Jeffrey D Marrazzo director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
2019, L.p. Gv 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Gv 2019 Gp, L.p. 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.p. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
2021, L.p. Gv 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Robert Nelsen director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Thomas Cahill director PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Arch Venture Partners X, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Carman Alenson officer: See Remarks 88 SIDNEY STREET, CAMBRIDGE MA 02139
Keith Crandell 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Kaye I Foster-cheek director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Meredith Goldwasser officer: SVP, Strategy & Corporate Ops. PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139